Effects of Cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study)

Neuroscience and Behavioral Physiology

Volumn 38, Issue 6, 2008, Pages 639-645

  Damulin, I V ^a   Koberskaya, N N ^a   Mkhitaryan, E A ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

300 cognitive evoked potentials; Cerebral vascular insufficiency; Cerebrolysin; Impairment of cognitive functions

Indexed keywords

CEREBROLYSIN;

ADULT; AGED; ARTICLE; ATTENTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; EVENT RELATED POTENTIAL; FEMALE; HUMAN; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; ATTENTION; BRAIN; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; CONCEPT FORMATION; EVENT-RELATED POTENTIALS, P300; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NEUROTENSIN; NOOTROPIC AGENTS; PROBLEM SOLVING; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 48949097635     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-008-9014-5     Document Type: Article

References (41)

1. N. V. Vereshchagin and N. V. Lebedeva, "Mild forms of multi-infarct dementia: Efficacy of cerebrolysin," Sov. Med., 11, 6-8 (1991).
2. B. S. Vilenskii, Stroke [in Russian], MIA, St. Petersburg (1995).
3. B. S. Vilenskii, G. M. Semenova, and E. A. Shirokov, "Use of cerebrolysin in ischemic stroke," Zh. Nevrol. Psikhiat., 99, No. 4, 65-69 (1999).
4. M. Windisch, "Cerebrolysin - new results supporting multilateral actions," in: Third International Symposium on Cerebrolysin [in Russian], Moscow (1991), pp. 81-106.
5. V. V. Gnezditskii, Evoked Potentials in Clinical Practice [in Russian], Medpress-Inform, Moscow (2003).
6. E. I. Gusev and V. I. Skvortsova, Brain Ischemia [in Russian], Meditsina, Moscow (2001).
7. I. V. Damulin, "Use of cerebrolysin in vascular dementia and Alzheimer's disease," Ros. Med. Zh., 25, 1150-1156 (2002).
8. V. V. Zakharov and N. N. Yakhno, "Cognitive impairments in the aged and elderly," in: Methods for Doctors [in Russian], Moscow (2005).
9. V. V. Zakharov and I. V. Damulin, Diagnosis and Treatment of Impairments to Memory and Other Higher Brain Functions in the Elderly [in Russian], N. N. Yakhno (ed.), Moscow (1997).
10. L. R. Zenkov and M. A. Ronkin, Functional Diagnosis of Nervous Diseases [in Russian], Medpress-Inform, Moscow (2004).
11. N. N. Koberskaya, Clinical and Electrophysiological Characteristics of Cognitive Impairments in Parkinson's Disease and Symptomatic Parkinsonism [in Russian], Author's Abstract of Master's Thesis in Medical Sciences, Moscow (2003).
12. N. N. Koberskaya, "The P300 cognitive potential," Nevrol. Zh., 8, No. 6, 34-42 (2003).
13. N. K. Korsakova and L. I. Moskovichyute, Subcortical Brain Structures and Mental Processes [in Russian], Moscow State University, Moscow (1985).
14. A. B. Lokshina and V. V. Zakharov, "Mild and moderate cognitive disturbances in cerebral vascular insufficiency," Nevrol. Zh., 11 (Supplement 1), 57-64 (2006).
15. A. R. Luriya, Basic Neurology [in Russian], Academia, Moscow (2002).
16. V. A. Parfenov, A. A. Ryzhak, and Yu. A. Starchina, "Cognitive and emotional impairments in patients with arterial hypertension," Nevrol. Zh., 11, (Supplement 1), 47-53 (2006).
17. E. I. Chukanova, "Effects of cerebrolysin on the progression and development of stroke in patients with cerebral vascular insufficiency," Rus. Med. Zh., 14, No. 9, 652-657 (2006).
18. E. B. Shmidt, "Classification of vascular lesions of the brain," Zh. Nevropatol. Psikhiat., 9, 1281-1288 (1985).
19. N. N. Yakhno, "Cognitive disorders in neurological practice," Nevrol. Zh., 11 (Supplement 1), 4-13 (2006).
20. N. N. Yakhno and I. V. Damulin, "Cerebral vascular insufficiency," Ros. Med. Zh., 5, 3-7 (1999).
21. N. N. Yakhno, I. V. Damulin, V. V. Zakharov, et al., "Experience of the use of high doses of cerebrolysin in vascular dementia," Ter. Arkh., 68, No. 10, 65-69 (1996).
22. N. N. Yakhno, O. S. Levin, and I. V. Damulin, "Comparison of clinical and MRI data in cerebral vascular insufficiency. 2. Cognitive impairments," Nevrol. Zh., 6, No. 3, 10-18 (2001).
23. R. J. Boado, "In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides," Eur. J. Neurol., 6, Supplement 3, 37 (1999).
24. S. Duma and N. Mutz, "Wirsamkeit einer Peptid-Dextran-Kombination in der Behandlung von Schadel-Hirn-Verletzten," Neuropsychiatrie, 4, 69-72 (1990).
25. M. F. Folstein, S. E. Folstein, and P. R. McHugh, "'Mini-mental state:' A practical method for grading the cognitive state of patients for the clinician," J. Psychiat. Res., 12, 189-198 (1975).
26. S. Gauthier, "Results of a 6-month randomized placebo-controlled study with Cerebrolysin in Alzheimer's disease," Eur. J. Neurol., 6, Supplement 3, 28 (1999).
27. D. S. Goodin and M. J. Aminoff, "Electrophysiological differences between demented and nondemented patients with Parkinson's disease," Ann. Neurol., 21, 90-94 (1987).
28. F. Jelasic, "Klinische Erfahrungen mit Cerebrolysin bei schweren hirnorganischen Prozessen," 52, 1829-1831 (1976).
29. S. Koppi and G. S. Barolin, "Hamodilutionstherapie mit nervenzellstoffwechsel-aktiver Therapie beim ischamischen Insult: ermutigende Resultate einer Vergleichsstudie," Wien Med. Wochschr., 146, No. 3, 41-48 (1996).
30. D. E. J. Linden, "The P300: Where in the brain is it produced and what does it tell us?" Neuroscientist, 11, 563-576 (2005).
31. S. Mattis, Dementia Rating Scale, Psychological Assessment Resources, Inc., Odessa (1988).
32. V. Monfort, V. Pathousa, and R. Ragot, "Role of frontal cortex in memory for duration: An event-related potential study in humans," Neurosci. Lett., 286, 91-94 (2000).
33. R. C. Petersen, R. Doody, A. Kurz, et al., "Current concepts in mild cognitive impairment," Arch. Neurol., 58, 1985-1992 (2001).
34. J. Polich, J. E. Alexander, and L. O. Bauer, "P300 topography of amplitude/latency correlations," Brain Topogr., 9, 275-282 (1997).
35. J. Polich and A. Kok, "Cognitive and biological determinants of P300: An integrative review," Biol. Psychol., 41, 103-146 (1995).
36. E. Ruther, H. Moessler, and M. Windisch, "The MAD-B Study: A randomized, double-blind, placebo-controlled trial with a Cerebrolysin in Alzheimer's disease," Neurobiol. Aging, 21, No. 1, 28 (2000).
37. E. Ruther, R. Ritter, M. Apecechea, et al., "Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy," J. Neural Transm., 107, 815-829 (2000).
38. H. Tashibana, K. Kawabata, M. Takeda, et al., "Multimodal evoked potentials in Binswanger's disease and Alzheimer disease," Int. J. Neurosci., 69, No. 1/4, 197-206 (1993).
39. H. Tashibana, K. Toda, and M. Sugita, "Event-related potentials in patients with multiple lacunar infarcts," Gerontology, 38, No. 6, 322-329 (1992).
40. H. Tashibana, K. Toda, N. Yokota, et al., "Cerebral blood flow and event-related potential in patients with multiple cerebral infarcts," Int. J. Neurosci., 60, No. 1/2, 113-118 (1991).
41. M. Windisch, E. Albrecht, U. Eggenreich, and B. Paier, "Neurotrophic effects of the nootropic drug Cerebrolysin - a summary," in: Third International Conference on Alzheimer's Disease and Related Disorders, Padova (1992), pp. 4-5.